Age 0 3 0 3 B-age
≥18 4 7 4 7 O
years 8 13 8 13 I-lower_bound

CrCl 0 4 14 18 B-clinical_variable
= 5 6 19 20 O
( 7 8 21 22 O
140 8 11 22 25 B-lower_bound
- 12 13 26 27 O
age 14 17 28 31 B-age
in 18 20 32 34 O
years 21 26 35 40 O
) 26 27 40 41 O
x 28 29 42 43 O
weight 30 36 44 50 B-clinical_variable
in 37 39 51 53 O
kg 40 42 54 56 O
x 43 44 57 58 O
0.85 45 49 59 63 O
72 50 52 64 66 O
x 53 54 67 68 O
serum 55 60 69 74 B-clinical_variable
creatinine 61 71 75 85 I-clinical_variable
in 72 74 86 88 O
mg 75 77 89 91 O
/ 77 78 91 92 O
dL 78 80 92 94 O
Male 81 85 95 99 B-gender
CrCl 86 90 100 104 O
= 91 92 105 106 O
( 93 94 107 108 O
140 94 97 108 111 O
- 98 99 112 113 O
age 100 103 114 117 O
in 104 106 118 120 O
years 107 112 121 126 O
) 112 113 126 127 O
x 114 115 128 129 O
weight 116 122 130 136 O
in 123 125 137 139 O
kg 126 128 140 142 O
x 129 130 143 144 O
1.00 131 135 145 149 O
72 136 138 150 152 O
x 139 140 153 154 O
serum 141 146 155 160 O
creatinine 147 157 161 171 O
in 158 160 172 174 O
mg 161 163 175 177 O
/ 163 164 177 178 O
dL 164 166 178 180 O

Female 0 6 181 187 B-gender

History 0 7 188 195 O
of 8 10 196 198 O
severe 11 17 199 205 O
hypersensitivity 18 34 206 222 O
reaction 35 43 223 231 O
to 44 46 232 234 O
any 47 50 235 238 O
monoclonal 51 61 239 249 B-allergy_name
antibody 62 70 250 258 I-allergy_name

Inhaled 0 7 259 266 B-treatment
or 8 10 267 269 O
topical 11 18 270 277 B-treatment
steroids 19 27 278 286 I-treatment
and 28 31 287 290 O
adrenal 32 39 291 298 B-clinical_variable
replacement 40 51 299 310 I-clinical_variable
doses 52 57 311 316 I-clinical_variable
< 58 59 317 318 O
10 59 61 318 320 B-upper_bound
mg 62 64 321 323 I-upper_bound
daily 65 70 324 329 I-upper_bound
prednisone 71 81 330 340 O
equivalents 82 93 341 352 O

Patients 0 8 353 361 O
who 9 12 362 365 O
have 13 17 366 370 O
disease 18 25 371 378 O
relapse 26 33 379 386 O
, 33 34 386 387 O
active 35 41 388 394 O
GVHD 42 46 395 399 B-chronic_disease
or 47 49 400 402 O
history 50 57 403 410 O
of 58 60 411 413 O
more 61 65 414 418 O
than 66 70 419 423 O
Stage 71 76 424 429 B-lower_bound
1 77 78 430 431 I-lower_bound
skin 79 83 432 436 B-chronic_disease
acute 84 89 437 442 I-chronic_disease
GVHD 90 94 443 447 I-chronic_disease
, 94 95 447 448 O
history 96 103 449 456 O
of 104 106 457 459 O
cGVHD 107 112 460 465 B-chronic_disease

Patients 0 8 466 474 O
who 9 12 475 478 O
have 13 17 479 483 O
had 18 21 484 487 O
chemotherapy 22 34 488 500 B-treatment
or 35 37 501 503 O
radiotherapy 38 50 504 516 B-treatment
within 51 57 517 523 O
4 58 59 524 525 O
weeks 60 65 526 531 O
( 66 67 532 533 O
6 67 68 533 534 O
weeks 69 74 535 540 O
for 75 78 541 544 O
nitrosoureas 79 91 545 557 O
or 92 94 558 560 O
mitomycin 95 104 561 570 B-treatment
C 105 106 571 572 I-treatment
) 106 107 572 573 O
prior 108 113 574 579 O
to 114 116 580 582 O
entering 117 125 583 591 O
the 126 129 592 595 O
study 130 135 596 601 O
or 136 138 602 604 O
those 139 144 605 610 O
who 145 148 611 614 O
have 149 153 615 619 O
not 154 157 620 623 O
recovered 158 167 624 633 O
from 168 172 634 638 O
adverse 173 180 639 646 O
events 181 187 647 653 O
( 188 189 654 655 O
AEs 189 192 655 658 O
) 192 193 658 659 O
due 194 197 660 663 O
to 198 200 664 666 O
agents 201 207 667 673 O
administered 208 220 674 686 O
more 221 225 687 691 O
than 226 230 692 696 O
4 231 232 697 698 O
weeks 233 238 699 704 O
earlier 239 246 705 712 O

Patients 0 8 713 721 O
who 9 12 722 725 O
have 13 17 726 730 O
had 18 21 731 734 O
evidence 22 30 735 743 O
of 31 33 744 746 O
active 34 40 747 753 O
or 41 43 754 756 O
acute 44 49 757 762 B-chronic_disease
diverticulitis 50 64 763 777 I-chronic_disease
, 64 65 777 778 O
intra 66 71 779 784 B-chronic_disease
- 71 72 784 785 I-chronic_disease
abdominal 72 81 785 794 I-chronic_disease
abscess 82 89 795 802 I-chronic_disease
, 89 90 802 803 O
GI 91 93 804 806 B-chronic_disease
obstruction 94 105 807 818 I-chronic_disease
and 106 109 819 822 O
abdominal 110 119 823 832 B-cancer
carcinomatosis 120 134 833 847 I-cancer
which 135 140 848 853 O
are 141 144 854 857 O
known 145 150 858 863 O
risk 151 155 864 868 O
factors 156 163 869 876 O
for 164 167 877 880 O
bowel 168 173 881 886 O
perforation 174 185 887 898 O
should 186 192 899 905 O
be 193 195 906 908 O
evaluated 196 205 909 918 O
for 206 209 919 922 O
the 210 213 923 926 O
potential 214 223 927 936 O
need 224 228 937 941 O
for 229 232 942 945 O
additional 233 243 946 956 O
treatment 244 253 957 966 B-treatment
before 254 260 967 973 O
coming 261 267 974 980 O
on 268 270 981 983 O
study 271 276 984 989 O

Patients 0 8 990 998 O
with 9 13 999 1003 O
active 14 20 1004 1010 B-chronic_disease
autoimmune 21 31 1011 1021 I-chronic_disease
disease 32 39 1022 1029 I-chronic_disease
or 40 42 1030 1032 O
history 43 50 1033 1040 O
of 51 53 1041 1043 O
autoimmune 54 64 1044 1054 O
disease 65 72 1055 1062 O
that 73 77 1063 1067 O
might 78 83 1068 1073 O
recur 84 89 1074 1079 O
, 89 90 1079 1080 O
which 91 96 1081 1086 O
may 97 100 1087 1090 O
affect 101 107 1091 1097 O
vital 108 113 1098 1103 O
organ 114 119 1104 1109 O
function 120 128 1110 1118 O
or 129 131 1119 1121 O
require 132 139 1122 1129 O
immune 140 146 1130 1136 B-treatment
suppressive 147 158 1137 1148 I-treatment
treatment 159 168 1149 1158 I-treatment
including 169 178 1159 1168 O
systemic 179 187 1169 1177 B-treatment
corticosteroids 188 203 1178 1193 I-treatment

Patients 0 8 1194 1202 O
with 9 13 1203 1207 O
active 14 20 1208 1214 B-chronic_disease
infection 21 30 1215 1224 I-chronic_disease
, 30 31 1224 1225 O
un 32 34 1226 1228 O
- 34 35 1228 1229 O
resolving 35 44 1229 1238 O
more 45 49 1239 1243 O
than 50 54 1244 1248 O
grade 55 60 1249 1254 B-lower_bound
2 61 62 1255 1256 I-lower_bound
transplant 63 73 1257 1267 O
- 73 74 1267 1268 O
related 74 81 1268 1275 O
toxicities 82 92 1276 1286 O

Patients 0 8 1287 1295 O
with 9 13 1296 1300 O
hematologic 14 25 1301 1312 B-cancer
malignancies 26 38 1313 1325 I-cancer
status 39 45 1326 1332 O
post 46 50 1333 1337 B-treatment
allogeneic 51 61 1338 1348 I-treatment
SCT 62 65 1349 1352 I-treatment
without 66 73 1353 1360 O
evidence 74 82 1361 1369 O
of 83 85 1370 1372 O
disease 86 93 1373 1380 O
relapse 94 101 1381 1388 O
, 101 102 1388 1389 O
active 103 109 1390 1396 O
GVHD 110 114 1397 1401 B-chronic_disease
or 115 117 1402 1404 O
history 118 125 1405 1412 O
of 126 128 1413 1415 O
more 129 133 1416 1420 O
than 134 138 1421 1425 O
Stage 139 144 1426 1431 B-lower_bound
I 145 146 1432 1433 I-lower_bound
skin 147 151 1434 1438 B-chronic_disease
acute 152 157 1439 1444 I-chronic_disease
GVHD 158 162 1445 1449 I-chronic_disease

Patients 0 8 1450 1458 O
with 9 13 1459 1463 O
high 14 18 1464 1468 O
risk 19 23 1469 1473 O
myeloid 24 31 1474 1481 B-cancer
or 32 34 1482 1484 O
lymphoid 35 43 1485 1493 B-cancer
malignancies 44 56 1494 1506 I-cancer
at 57 59 1507 1509 O
stem 60 64 1510 1514 B-treatment
cell 65 69 1515 1519 I-treatment
transplant 70 80 1520 1530 I-treatment
following 81 90 1531 1540 O
ASBMT 91 96 1541 1546 O
criteria 97 105 1547 1555 O
( 106 107 1556 1557 O
http://www.asbmt.org/displaycommon.cfm?an=1&subarticlenbr=35 107 167 1557 1617 O
, 167 168 1617 1618 O
under 169 174 1619 1624 O
disease 175 182 1625 1632 O
classification 183 197 1633 1647 O
) 197 198 1647 1648 O
, 198 199 1648 1649 O
including 200 209 1650 1659 O
but 210 213 1660 1663 O
not 214 217 1664 1667 O
limited 218 225 1668 1675 O
to 226 228 1676 1678 O
conditions 229 239 1679 1689 O
listed 240 246 1690 1696 O

Patients 0 8 1697 1705 O
with 9 13 1706 1710 O
rheumatoid 14 24 1711 1721 B-chronic_disease
arthritis 25 34 1722 1731 I-chronic_disease
and 35 38 1732 1735 O
other 39 44 1736 1741 O
arthropathies 45 58 1742 1755 B-chronic_disease
, 58 59 1755 1756 O
Sjögren 60 67 1757 1764 B-chronic_disease
's 67 69 1764 1766 I-chronic_disease
syndrome 70 78 1767 1775 I-chronic_disease
and 79 82 1776 1779 O
psoriasis 83 92 1780 1789 B-chronic_disease
controlled 93 103 1790 1800 O
with 104 108 1801 1805 O
topical 109 116 1806 1813 B-treatment
medication 117 127 1814 1824 I-treatment
and 128 131 1825 1828 O
patients 132 140 1829 1837 O
with 141 145 1838 1842 O
positive 146 154 1843 1851 O
serology 155 163 1852 1860 B-treatment
, 163 164 1860 1861 O
such 165 169 1862 1866 O
as 170 172 1867 1869 O
antinuclear 173 184 1870 1881 B-treatment
antibodies 185 195 1882 1892 I-treatment
( 196 197 1893 1894 I-treatment
ANA 197 200 1894 1897 I-treatment
) 200 201 1897 1898 I-treatment
, 201 202 1898 1899 O
anti 203 207 1900 1904 B-treatment
- 207 208 1904 1905 I-treatment
thyroid 208 215 1905 1912 I-treatment
antibodies 216 226 1913 1923 I-treatment
should 227 233 1924 1930 O
be 234 236 1931 1933 O
evaluated 237 246 1934 1943 O
for 247 250 1944 1947 O
the 251 254 1948 1951 O
presence 255 263 1952 1960 O
of 264 266 1961 1963 O
target 267 273 1964 1970 O
organ 274 279 1971 1976 O
involvement 280 291 1977 1988 O
and 292 295 1989 1992 O
potential 296 305 1993 2002 O
need 306 310 2003 2007 O
for 311 314 2008 2011 O
systemic 315 323 2012 2020 B-treatment
treatment 324 333 2021 2030 I-treatment

Patients 0 8 2031 2039 O
with 9 13 2040 2044 O
vitiligo 14 22 2045 2053 B-chronic_disease
, 22 23 2053 2054 O
endocrine 24 33 2055 2064 B-chronic_disease
deficiencies 34 46 2065 2077 I-chronic_disease
including 47 56 2078 2087 O
thyroiditis 57 68 2088 2099 B-chronic_disease
managed 69 76 2100 2107 O
with 77 81 2108 2112 O
replacement 82 93 2113 2124 O
hormones 94 102 2125 2133 O
including 103 112 2134 2143 O
physiologic 113 124 2144 2155 O
corticosteroids 125 140 2156 2171 B-treatment

Refractory 0 10 2172 2182 B-cancer
acute 11 16 2183 2188 I-cancer
myelogenous 17 28 2189 2200 I-cancer
or 29 31 2201 2203 I-cancer
lymphoid 32 40 2204 2212 I-cancer
leukemia 41 49 2213 2221 I-cancer
Relapsed 50 58 2222 2230 B-cancer
acute 59 64 2231 2236 I-cancer
myelogenous 65 76 2237 2248 I-cancer
or 77 79 2249 2251 I-cancer
lymphoid 80 88 2252 2260 I-cancer
leukemia 89 97 2261 2269 I-cancer
Myelodysplastic 98 113 2270 2285 B-cancer
syndromes 114 123 2286 2295 I-cancer
with 124 128 2296 2300 O
5 129 130 2301 2302 O
% 130 131 2302 2303 O
or 132 134 2304 2306 O
more 135 139 2307 2311 O
blasts 140 146 2312 2318 O
Chronic 147 154 2319 2326 B-cancer
myelogenous 155 166 2327 2338 I-cancer
leukemia 167 175 2339 2347 I-cancer
in 176 178 2348 2350 O
chronic 179 186 2351 2358 O
phase 187 192 2359 2364 O
3 193 194 2365 2366 B-lower_bound
or 195 197 2367 2369 O
more 198 202 2370 2374 O
, 202 203 2374 2375 O
blast 204 209 2376 2381 O
phase 210 215 2382 2387 O
presently 216 225 2388 2397 O
, 225 226 2397 2398 O
or 227 229 2399 2401 O
second 230 236 2402 2408 O
accelerated 237 248 2409 2420 O
phase 249 254 2421 2426 O
, 254 255 2426 2427 O
Recurrent 256 265 2428 2437 B-cancer
or 266 268 2438 2440 I-cancer
refractory 269 279 2441 2451 I-cancer
malignant 280 289 2452 2461 I-cancer
lymphoma 290 298 2462 2470 I-cancer
or 299 301 2471 2473 O
Hodgkin 302 309 2474 2481 B-cancer
's 309 311 2481 2483 I-cancer
disease 312 319 2484 2491 I-cancer
with 320 324 2492 2496 O
less 325 329 2497 2501 O
than 330 334 2502 2506 O
a 335 336 2507 2508 O
partial 337 344 2509 2516 O
response 345 353 2517 2525 O
at 354 356 2526 2528 O
transplant 357 367 2529 2539 B-treatment
High 368 372 2540 2544 O
risk 373 377 2545 2549 O
chronic 378 385 2550 2557 B-cancer
lymphocytic 386 397 2558 2569 I-cancer
leukemia 398 406 2570 2578 I-cancer
defined 407 414 2579 2586 O
as 415 417 2587 2589 O
no 418 420 2590 2592 O
response 421 429 2593 2601 O
or 430 432 2602 2604 O
stable 433 439 2605 2611 O
disease 440 447 2612 2619 O
to 448 450 2620 2622 O
the 451 454 2623 2626 O
most 455 459 2627 2631 O
recent 460 466 2632 2638 O
treatment 467 476 2639 2648 B-treatment
regimen 477 484 2649 2656 I-treatment

Serum 0 5 2657 2662 B-clinical_variable
creatinine 6 16 2663 2673 I-clinical_variable
≤1.5× 17 22 2674 2679 O
ULN 23 26 2680 2683 I-upper_bound
OR 27 29 2684 2686 O

Uncontrolled 0 12 2687 2699 O
intercurrent 13 25 2700 2712 B-chronic_disease
illness 26 33 2713 2720 I-chronic_disease
including 34 43 2721 2730 O
, 43 44 2730 2731 O
but 45 48 2732 2735 O
not 49 52 2736 2739 O
limited 53 60 2740 2747 O
to 61 63 2748 2750 O
, 63 64 2750 2751 O
ongoing 65 72 2752 2759 O
or 73 75 2760 2762 O
active 76 82 2763 2769 B-chronic_disease
infection 83 92 2770 2779 I-chronic_disease
, 92 93 2779 2780 O
symptomatic 94 105 2781 2792 O
congestive 106 116 2793 2803 B-chronic_disease
heart 117 122 2804 2809 I-chronic_disease
failure 123 130 2810 2817 I-chronic_disease
, 130 131 2817 2818 O
unstable 132 140 2819 2827 B-chronic_disease
angina 141 147 2828 2834 I-chronic_disease
pectoris 148 156 2835 2843 I-chronic_disease
, 156 157 2843 2844 O
cardiac 158 165 2845 2852 B-chronic_disease
arrhythmia 166 176 2853 2863 I-chronic_disease
, 176 177 2863 2864 O
or 178 180 2865 2867 O
psychiatric 181 192 2868 2879 B-chronic_disease
illness 193 200 2880 2887 I-chronic_disease
/ 200 201 2887 2888 I-chronic_disease
social 201 207 2888 2894 I-chronic_disease
situations 208 218 2895 2905 I-chronic_disease
that 219 223 2906 2910 O
would 224 229 2911 2916 O
limit 230 235 2917 2922 O
compliance 236 246 2923 2933 O
with 247 251 2934 2938 O
study 252 257 2939 2944 O
requirements 258 270 2945 2957 O

WOCBP 0 5 2958 2963 O
receiving 6 15 2964 2973 O
nivolumab 16 25 2974 2983 B-treatment
will 26 30 2984 2988 O
be 31 33 2989 2991 O
instructed 34 44 2992 3002 O
to 45 47 3003 3005 O
adhere 48 54 3006 3012 B-contraception_consent
to 55 57 3013 3015 I-contraception_consent
contraception 58 71 3016 3029 I-contraception_consent
for 72 75 3030 3033 O
a 76 77 3034 3035 O
period 78 84 3036 3042 O
of 85 87 3043 3045 O
23 88 90 3046 3048 O
weeks 91 96 3049 3054 O
( 97 98 3055 3056 O
30 98 100 3056 3058 O
days 101 105 3059 3063 O
plus 106 110 3064 3068 O
the 111 114 3069 3072 O
time 115 119 3073 3077 O
required 120 128 3078 3086 O
for 129 132 3087 3090 O
nivolumab 133 142 3091 3100 O
to 143 145 3101 3103 O
undergo 146 153 3104 3111 O
five 154 158 3112 3116 O
half 159 163 3117 3121 O
- 163 164 3121 3122 O
lives 164 169 3122 3127 O
) 169 170 3127 3128 O
after 171 176 3129 3134 O
the 177 180 3135 3138 O
last 181 185 3139 3143 O
dose 186 190 3144 3148 O
of 191 193 3149 3151 O
investigational 194 209 3152 3167 O
product 210 217 3168 3175 O

WOCBP 0 5 3176 3181 O
should 6 12 3182 3188 O
use 13 16 3189 3192 O
an 17 19 3193 3195 O
adequate 20 28 3196 3204 O
method 29 35 3205 3211 O
to 36 38 3212 3214 O
avoid 39 44 3215 3220 O
pregnancy 45 54 3221 3230 B-pregnancy
for 55 58 3231 3234 O
23 59 61 3235 3237 O
weeks 62 67 3238 3243 O
) 67 68 3243 3244 O
after 69 74 3245 3250 O
the 75 78 3251 3254 O
last 79 83 3255 3259 O
dose 84 88 3260 3264 O
of 89 91 3265 3267 O
investigational 92 107 3268 3283 O
drug 108 112 3284 3288 O
Nivolumab 113 122 3289 3298 B-treatment

Women 0 5 3299 3304 B-gender
must 6 10 3305 3309 O
not 11 14 3310 3313 O
be 15 17 3314 3316 O
breastfeeding 18 31 3317 3330 O

Women 0 5 3331 3336 B-gender
of 6 8 3337 3339 O
childbearing 9 21 3340 3352 O
potential 22 31 3353 3362 O
( 32 33 3363 3364 O
WOCBP 33 38 3364 3369 O
) 38 39 3369 3370 O
is 40 42 3371 3373 O
defined 43 50 3374 3381 O
as 51 53 3382 3384 O
any 54 57 3385 3388 O
female 58 64 3389 3395 B-gender
who 65 68 3396 3399 O
has 69 72 3400 3403 O
experienced 73 84 3404 3415 O
menarche 85 93 3416 3424 O
and 94 97 3425 3428 O
who 98 101 3429 3432 O
has 102 105 3433 3436 O
not 106 109 3437 3440 O
undergone 110 119 3441 3450 O
surgical 120 128 3451 3459 O
sterilization 129 142 3460 3473 O
( 143 144 3474 3475 O
hysterectomy 144 156 3475 3487 B-treatment
or 157 159 3488 3490 O
bilateral 160 169 3491 3500 B-treatment
oophorectomy 170 182 3501 3513 I-treatment
) 182 183 3513 3514 O
or 184 186 3515 3517 O
who 187 190 3518 3521 O
is 191 193 3522 3524 O
not 194 197 3525 3528 O
postmenopausal 198 212 3529 3543 O

Women 0 5 3544 3549 B-gender
of 6 8 3550 3552 O
childbearing 9 21 3553 3565 O
potential 22 31 3566 3575 O
must 32 36 3576 3580 O
have 37 41 3581 3585 O
a 42 43 3586 3587 O
negative 44 52 3588 3596 B-pregnancy
serum 53 58 3597 3602 I-pregnancy
or 59 61 3603 3605 I-pregnancy
urine 62 67 3606 3611 I-pregnancy
pregnancy 68 77 3612 3621 I-pregnancy
test 78 82 3622 3626 O
( 83 84 3627 3628 O
minimum 84 91 3628 3635 O
sensitivity 92 103 3636 3647 O
25 104 106 3648 3650 B-lower_bound
IU 107 109 3651 3653 I-lower_bound
/ 109 110 3653 3654 I-lower_bound
L 110 111 3654 3655 I-lower_bound
or 112 114 3656 3658 O
equivalent 115 125 3659 3669 O
units 126 131 3670 3675 O
of 132 134 3676 3678 O
HCG 135 138 3679 3682 B-clinical_variable
) 138 139 3682 3683 O
within 140 146 3684 3690 O
24 147 149 3691 3693 B-upper_bound
hours 150 155 3694 3699 I-upper_bound
prior 156 161 3700 3705 I-upper_bound
to 162 164 3706 3708 O
the 165 168 3709 3712 O
start 169 174 3713 3718 O
of 175 177 3719 3721 O
nivolumab 178 187 3722 3731 B-treatment

Women 0 5 3732 3737 B-gender
who 6 9 3738 3741 O
are 10 13 3742 3745 O
not 14 17 3746 3749 O
of 18 20 3750 3752 O
childbearing 21 33 3753 3765 O
potential 34 43 3766 3775 O
( 44 45 3776 3777 O
i.e. 45 49 3777 3781 O
, 49 50 3781 3782 O
who 51 54 3783 3786 O
are 55 58 3787 3790 O
postmenopausal 59 73 3791 3805 O
or 74 76 3806 3808 O
surgically 77 87 3809 3819 O
sterile 88 95 3820 3827 O
as 96 98 3828 3830 O
well 99 103 3831 3835 O
as 104 106 3836 3838 O
azoospermic 107 118 3839 3850 O
men 119 122 3851 3854 O
) 122 123 3854 3855 O
do 124 126 3856 3858 O
not 127 130 3859 3862 O
require 131 138 3863 3870 O
contraception 139 152 3871 3884 O

absolute 0 8 3885 3893 B-clinical_variable
neutrophil 9 19 3894 3904 I-clinical_variable
count 20 25 3905 3910 I-clinical_variable
≥1,000 26 32 3911 3917 O
/ 32 33 3917 3918 I-lower_bound
mcL 33 36 3918 3921 I-lower_bound

creatinine 0 10 3922 3932 B-clinical_variable
clearance 11 20 3933 3942 I-clinical_variable
( 21 22 3943 3944 I-clinical_variable
CrCl 22 26 3944 3948 I-clinical_variable
) 26 27 3948 3949 I-clinical_variable
≥40 28 31 3950 3953 O
mL 32 34 3954 3956 I-lower_bound
/ 34 35 3956 3957 I-lower_bound
min 35 38 3957 3960 I-lower_bound

leukocytes 0 10 3961 3971 B-clinical_variable
≥2000 11 16 3972 3977 O
/ 16 17 3977 3978 I-lower_bound
mcL 17 20 3978 3981 I-lower_bound

patients 0 8 3982 3990 O
with 9 13 3991 3995 O
Gilbert 14 21 3996 4003 B-chronic_disease
Syndrome 22 30 4004 4012 I-chronic_disease

patients 0 8 4013 4021 O
with 9 13 4022 4026 O
a 14 15 4027 4028 O
history 16 23 4029 4036 O
of 24 26 4037 4039 O
immune 27 33 4040 4046 B-chronic_disease
related 34 41 4047 4054 I-chronic_disease
neurologic 42 52 4055 4065 I-chronic_disease
disease 53 60 4066 4073 I-chronic_disease
, 60 61 4073 4074 O
multiple 62 70 4075 4083 B-chronic_disease
sclerosis 71 80 4084 4093 I-chronic_disease
, 80 81 4093 4094 O
autoimmune 82 92 4095 4105 B-chronic_disease
( 93 94 4106 4107 I-chronic_disease
demyelinating 94 107 4107 4120 I-chronic_disease
) 107 108 4120 4121 I-chronic_disease
neuropathy 109 119 4122 4132 I-chronic_disease
, 119 120 4132 4133 O
Guillain 121 129 4134 4142 B-chronic_disease
- 129 130 4142 4143 I-chronic_disease
Barre 130 135 4143 4148 I-chronic_disease
syndrome 136 144 4149 4157 I-chronic_disease
, 144 145 4157 4158 O
myasthenia 146 156 4159 4169 B-chronic_disease
gravis 157 163 4170 4176 I-chronic_disease
; 163 164 4176 4177 O
systemic 165 173 4178 4186 B-chronic_disease
autoimmune 174 184 4187 4197 I-chronic_disease
disease 185 192 4198 4205 I-chronic_disease
such 193 197 4206 4210 O
as 198 200 4211 4213 O
SLE 201 204 4214 4217 B-chronic_disease
, 204 205 4217 4218 O
connective 206 216 4219 4229 B-chronic_disease
tissue 217 223 4230 4236 I-chronic_disease
diseases 224 232 4237 4245 I-chronic_disease
, 232 233 4245 4246 O
scleroderma 234 245 4247 4258 B-chronic_disease
, 245 246 4258 4259 O
inflammatory 247 259 4260 4272 B-chronic_disease
bowel 260 265 4273 4278 I-chronic_disease
disease 266 273 4279 4286 I-chronic_disease
( 274 275 4287 4288 I-chronic_disease
IBD 275 278 4288 4291 I-chronic_disease
) 278 279 4291 4292 I-chronic_disease
, 279 280 4292 4293 O
Crohn 281 286 4294 4299 B-chronic_disease
's 286 288 4299 4301 I-chronic_disease
, 288 289 4301 4302 O
ulcerative 290 300 4303 4313 B-chronic_disease
colitis 301 308 4314 4321 I-chronic_disease
, 308 309 4321 4322 O
hepatitis 310 319 4323 4332 B-chronic_disease
; 319 320 4332 4333 O
and 321 324 4334 4337 O
patients 325 333 4338 4346 O
with 334 338 4347 4351 O
a 339 340 4352 4353 O
history 341 348 4354 4361 O
of 349 351 4362 4364 O
toxic 352 357 4365 4370 B-chronic_disease
epidermal 358 367 4371 4380 I-chronic_disease
necrolysis 368 378 4381 4391 I-chronic_disease
( 379 380 4392 4393 I-chronic_disease
TEN 380 383 4393 4396 I-chronic_disease
) 383 384 4396 4397 I-chronic_disease
, 384 385 4397 4398 O
Stevens 386 393 4399 4406 B-chronic_disease
- 393 394 4406 4407 I-chronic_disease
Johnson 394 401 4407 4414 I-chronic_disease
syndrome 402 410 4415 4423 I-chronic_disease
, 410 411 4423 4424 O
or 412 414 4425 4427 O
phospholipid 415 427 4428 4440 B-chronic_disease
syndrome 428 436 4441 4449 I-chronic_disease

recovery 0 8 4450 4458 O
to 9 11 4459 4461 O
the 12 15 4462 4465 O
baseline 16 24 4466 4474 O
count(in 25 33 4475 4483 O
the 34 37 4484 4487 O
absence 38 45 4488 4495 O
of 46 48 4496 4498 O
transfusion)Hgb 49 64 4499 4514 O
> 65 66 4515 4516 O
9.0g 66 70 4516 4520 B-lower_bound
/ 70 71 4520 4521 I-lower_bound
dL 71 73 4521 4523 I-lower_bound

total 0 5 4524 4529 B-clinical_variable
bilirubin 6 15 4530 4539 I-clinical_variable
≤1.5× 16 21 4540 4545 O
institutional 22 35 4546 4559 I-upper_bound
upper 36 41 4560 4565 I-upper_bound
limit 42 47 4566 4571 I-upper_bound
of 48 50 4572 4574 I-upper_bound
normal 51 57 4575 4581 I-upper_bound
( 58 59 4582 4583 I-upper_bound
ULN 59 62 4583 4586 I-upper_bound
) 62 63 4586 4587 I-upper_bound

